Alerts will be sent to your verified email
Verify Email
MEDINOV
|
Medinova Diagnostic
|
Tejnaksh Healthcare
|
Transgene Biotek
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
-30.99 % | 10.88 % | -39.86 % |
|
5yr average Equity Multiplier
|
-0.78 | 1.46 | 9.29 |
|
5yr Average Asset Turnover Ratio
|
2.63 | 0.48 | 0.0 |
|
5yr Avg Net Profit Margin
|
13.18 % | 15.96 % | -67187.68 % |
|
Price to Book
|
0.0 | 1.47 | 3.39 |
|
P/E
|
20.89 | 16.52 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
-858.85 Days | -56.42 Days | 65.65 Days |
|
Inventory Days
|
4.43 Days | 20.02 Days | 866.48 Days |
|
Days Receivable
|
20.26 Days | 31.48 Days | 13.05 Days |
|
Days Payable
|
997.21 Days | 141.3 Days | 1913.74 Days |
|
5yr Average Interest Coverage Ratio
|
4.07 | 5.93 | -24.4 |
|
5yr Avg ROCE
|
124.73 % | 13.18 % | -5.18 % |
|
5yr Avg Operating Profit Margin
|
24.48 % | 30.73 % | -5270.55 % |
|
5 yr average Debt to Equity
|
-0.98 | 0.32 | 0.8 |
|
5yr CAGR Net Profit
|
n/a | -3.16 % | -42.99 % |
|
5yr Average Return on Assets
|
36.96 % | 7.4 % | -4.99 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
62.14 % | 73.83 % | 23.64 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Medinova Diagnostic
|
Tejnaksh Healthcare
|
Transgene Biotek
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|